Dong, R;
Lu, Q;
Kang, H;
Suridjan, I;
Kollmorgen, G;
Wild, N;
Deming, Y;
... Engelman, CD; + view all
(2023)
CSF metabolites associated with biomarkers of Alzheimer’s disease pathology.
Frontiers in Aging Neuroscience
, 15
, Article 1214932. 10.3389/fnagi.2023.1214932.
Preview |
PDF
fnagi-15-1214932.pdf - Published Version Download (5MB) | Preview |
Abstract
INTRODUCTION: Metabolomics technology facilitates studying associations between small molecules and disease processes. Correlating metabolites in cerebrospinal fluid (CSF) with Alzheimer’s disease (AD) CSF biomarkers may elucidate additional changes that are associated with early AD pathology and enhance our knowledge of the disease. METHODS: The relative abundance of untargeted metabolites was assessed in 161 individuals from the Wisconsin Registry for Alzheimer’s Prevention. A metabolome-wide association study (MWAS) was conducted between 269 CSF metabolites and protein biomarkers reflecting brain amyloidosis, tau pathology, neuronal and synaptic degeneration, and astrocyte or microglial activation and neuroinflammation. Linear mixed-effects regression analyses were performed with random intercepts for sample relatedness and repeated measurements and fixed effects for age, sex, and years of education. The metabolome-wide significance was determined by a false discovery rate threshold of 0.05. The significant metabolites were replicated in 154 independent individuals from then Wisconsin Alzheimer’s Disease Research Center. Mendelian randomization was performed using genome-wide significant single nucleotide polymorphisms from a CSF metabolites genome-wide association study. RESULTS: Metabolome-wide association study results showed several significantly associated metabolites for all the biomarkers except Aβ42/40 and IL-6. Genetic variants associated with metabolites and Mendelian randomization analysis provided evidence for a causal association of metabolites for soluble triggering receptor expressed on myeloid cells 2 (sTREM2), amyloid β (Aβ40), α-synuclein, total tau, phosphorylated tau, and neurogranin, for example, palmitoyl sphingomyelin (d18:1/16:0) for sTREM2, and erythritol for Aβ40 and α-synuclein. DISCUSSION: This study provides evidence that CSF metabolites are associated with AD-related pathology, and many of these associations may be causal.
| Type: | Article |
|---|---|
| Title: | CSF metabolites associated with biomarkers of Alzheimer’s disease pathology |
| Location: | Switzerland |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3389/fnagi.2023.1214932 |
| Publisher version: | https://doi.org/10.3389/fnagi.2023.1214932 |
| Language: | English |
| Additional information: | © 2023 Dong, Lu, Kang, Suridjan, Kollmorgen, Wild, Deming, Van Hulle, Anderson, Zetterberg, Blennow, Carlsson, Asthana, Johnson and Engelman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). |
| Keywords: | Alzheimer’s disease, CSF NeuroToolKit biomarkers, Mendelian randomization, metabolome-wide association, metabolomics |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10178218 |
Archive Staff Only
 |
View Item |
